• Explore /
  • Poster
  • / Neoadjuvant atezolizumab in resectable NSCLC patients: Updated clinical and immunophenotyping results from a multicenter trial.

Neoadjuvant atezolizumab in resectable NSCLC patients: Updated clinical and immunophenotyping results from a multicenter trial.

Abstract Poster

Authors

null

Filiz Oezkan

The Ohio State University, Arthur G. James Thoracic Cancer Center, Columbus, OH

Filiz Oezkan, Kai He, Dwight Hall Owen, Maciej Pietrzak, Valerie W. Rusch, Jamie E. Chaft, Rhonda Kitzler, Alan Nicholas, Katja Schulze, Ann Johnson, See Phan, Paul A. Bunn, Mark G. Kris, David J. Kwiatkowski, Bruce E. Johnson, Ignacio Ivan Wistuba, Jay M. Lee, Fred R. Hirsch, Gerard Lozanski, David Paul Carbone

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies

Sub Track

Immune Checkpoints and Stimulatory Receptors

Clinical Trial Registration Number

NCT02927301

Citation

J Clin Oncol 37, 2019 (suppl 8; abstr 99)

DOI

10.1200/JCO.2019.37.8_suppl.99

Abstract #

99

Poster Bd #

A1

Abstract Disclosures

Similar Posters

First Author: Yuming Zhu

First Author: Valerie W. Rusch

First Author: Hailiang Zhang

First Author: Dwight Hall Owen